<DOC>
	<DOCNO>NCT01069003</DOCNO>
	<brief_summary>EDUCATE prospective , multi-center study design collect real-world safety clinical outcome subject receive one Endeavor Zotarolimus-Eluting Stents either clopidogrel aspirin prasugrel aspirin part dual antiplatelet therapy ( DAPT ) drug regimen .</brief_summary>
	<brief_title>EDUCATE : The MEDTRONIC Endeavor Drug Eluting Stenting : Understanding Care , Antiplatelet Agents Thrombotic Events</brief_title>
	<detailed_description>To provide clinical information rate late late stent thrombosis Endeavor Drug-eluting Stent ( DES ) placement comer population broad range bleed thrombosis risk . EDUCATE analyze current practice clinician regard temporary cessation antiplatelet therapy association clinical outcome . In addition , patient include broad Endeavor registry also contribute DAPT native study population analysis 12 v 30 month duration dual antiplatelet therapy .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>ENROLLMENT INCLUSION CRITERIA Patient old 18 year . The patient patient 's legal representative consent participate authorize collection release medical information sign `` Subject Informed Consent Form '' . Patients undergo percutaneous intervention Endeavor stent deployment ( within 24 hour ) . The patient willing able cooperate study procedure require follow visit . ENROLLMENT EXCLUSION CRITERIA Index procedure stent placement stent diameter &lt; 2.5 mm &gt; 3.5 mm . Pregnant woman . Current medical condition life expectancy le 3 year . The patient currently participate another investigational device drug study clinically interfere EDUCATE Study . The patient may enrol EDUCATE Study . Patients hypersensitivity allergies one drug component indicate Instructions Use . Patients antiplatelet and/or anticoagulation therapy contraindicate . Patients treat stent Endeavor stent index procedure . RANDOMIZATION INCLUSION CRITERIA AT 12 MONTHS Subject `` 12 Month Clear '' . Subjects without know contraindication dual antiplatelet therapy least 18 month randomization . RANDOMIZATION EXCLUSION CRITERIA AT 12 MONTHS Pregnant woman . Subject switch thienopyridine type dose within 6 month prior randomization . Planned surgery necessitate discontinuation antiplatelet therapy within 18 month follow randomization . Percutaneous coronary intervention cardiac surgery 6 week post index procedure randomization . Planned surgery necessitate discontinuation antiplatelet therapy within 21 month follow randomization . Current medical condition life expectancy le 3 year . Subjects warfarin similar anticoagulant therapy .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Heart Disease</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
	<keyword>Dual Antiplatelet Therapy</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Prasugrel</keyword>
	<keyword>Vascular Disease</keyword>
	<keyword>Myocardial Ischemia</keyword>
</DOC>